Researchers find that repeated SNAC exposure altered gut bacteria and increased inflammatory markers in an animal study. While this does not show that SNAC directly causes harm, it highlights an ...

Hims & Hers Health, Inc. faces volatile earnings as compounded GLP-1 setbacks pressure shares. Click for this HIMS stock earnings preview.

In A Nutshell A new animal study found that SNAC, the absorption-boosting additive in Rybelsus (oral semaglutide), was linked ...

Blockbuster weight-loss drugs are transforming the way we treat obesity. But while costly injectable versions remain out of ...

GoodRx reports that the FDA has approved oral semaglutide (Wegovy) for weight loss, offering an alternative to injections with similar results.

A new study from Adelaide University is turning a spotlight on those tablet versions, finding that the absorption-enhancing ingredient salcaprozate sodium (SNAC) may have measurable adverse biological ...

Demand for GLP-1 drugs continues to climb, boosted by a major price drop and the FDA’s approval of an oral Wegovy pill that ...

Eli Lilly and Company LLY is one of the two clear leaders in the rapidly expanding diabetes and obesity treatment market, ...

GLP-1 weight loss drugs have quickly moved from medical journals to household conversations, reshaping how Americans think about obesity, diabetes and weight loss. Headlines often describe them as ...

Novo Nordisk NVO shares have plunged 20.5% in the past month. The massive sell-off of the stock was primarily driven by a weaker-than-expected 2026 financial outlook issued by the company, despite its ...

The European Commission (EC) has approved a higher dose of Novo Nordisk’s Wegovy (semaglutide), marking a win for the ...

This article was reviewed by Darragh O’Carroll, MD. Key Takeaways: GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity ...